Our Technology
Hemanext One
The Hemanext ONE® system enables processing and storage of oxygen and carbon dioxide reduced red blood cells. Our system seeks to provide a more consistent and higher quality red blood cell (RBC) by removing the fuel for oxidative damage.

PLEASE NOTE
The FDA has not cleared or approved the Hemanext ONE system, and it is not available for commercial distribution in the United States. If you are a resident of the European Union, please click below for our site for healthcare professionals
MVA video
The Hemanext ONE® process is designed to reduce progressive damage to red blood cells during storage. This can be seen through the MicroVascular analysis (MVA), showing the effects of storage on RBCs. In an MVA test conducted by Hemanext Inc, RBCs were observed at Day 0 and at Day 42 using conventional blood bank storage techniques and the Hemanext ONE® storage system.
The Hemanext MVA Test is for Research Use Only.
Informational Brochures
Explore information on the need for Hemanext ONE®
Hemanext History
Hemanext Research
Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.